Trial Profile

An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegvisomant (Primary)
Indications Acromegaly; Gigantism; Growth disorders
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Jul 2025 Status changed from recruiting to active, no longer recruiting.
16 Aug 2023 Planned number of patients changed from 140 to 120.
23 Dec 2022 Planned End Date changed from 1 Jan 2024 to 30 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com